# Implementing a Tiered Genetic Testing Strategy for Muscular Dystrophies in Morocco: From Targeted Assays to Exome Sequencing

**Authors:** Yasmina Rahmuni, Ilham Ratbi, Jaber Lyahyai, Imane Cherkaoui Jaouad, Ourayna Batta, Aziza Sbiti, Maryem Sahli, Omar Askander, Zineb Rchiad, Abdelaziz Sefiani

PMC · DOI: 10.1002/mgg3.70192 · Molecular Genetics & Genomic Medicine · 2026-02-25

## TL;DR

A tiered genetic testing strategy in Morocco helps diagnose muscular dystrophies, with half of cases resolved using cost-effective first-line tests and additional diagnoses through advanced sequencing.

## Contribution

The study introduces a stepwise genetic testing approach tailored for Moroccan populations, combining targeted and broad sequencing methods.

## Key findings

- Nearly half of muscular dystrophy cases were resolved using first-line tests like MPCR and Sanger sequencing.
- Genes SGCA, CAPN3, and FKRP were frequently mutated after DMD and SGCG, indicating population-specific alleles.
- Combining targeted and broad genomic approaches improved diagnosis rates despite resource limitations.

## Abstract

Muscular dystrophies (MDs) are a heterogeneous group of inherited neuromuscular disorders. In Morocco, where consanguinity is common, recurrent variants have been reported; however, the overall molecular landscape remains underexplored.

We analyzed 716 patients referred over 32 years for suspected limb‐girdle muscular dystrophy (LGMD) or dystrophinopathy using a stepwise approach. Multiplex PCR (MPCR) for DMD deletions and targeted Sanger sequencing of the SGCG:c.525delT variant were performed as first‐line tests. Unsolved patients underwent next‐generation sequencing (NGS), either via a customized gene panel or whole‐exome sequencing (WES).

Multiplex PCR for DMD deletions and targeted Sanger sequencing of the SGCG:c.525delT variant resolved nearly half of cases, demonstrating the efficiency of these cost‐effective first‐line tests. Unsolved patients underwent next‐generation sequencing (NGS), via a customized gene panel or whole‐exome sequencing (WES), though resource limitations prevented full coverage. Among tested cases, SGCA, CAPN3, and FKRP were the most frequently mutated genes after DMD and SGCG, with several novel or recurrent variants suggesting population‐specific alleles.

These results highlight the genetic heterogeneity of MDs in Morocco and the value of combining targeted and broad genomic approaches, while underscoring the need to extend NGS to fully characterize unresolved patients.

Targeted routine testing combined with NGS approaches enabled effective genetic diagnosis of muscular dystrophies in Moroccan patients, with nearly half of cases resolved by first‐line testing and additional diagnoses obtained through targeted sequencing and whole‐exome sequencing.

## Linked entities

- **Genes:** DMD (dystrophin) [NCBI Gene 1756], SGCG (sarcoglycan gamma) [NCBI Gene 6445], SGCA (sarcoglycan alpha) [NCBI Gene 6442], CAPN3 (calpain 3) [NCBI Gene 825], FKRP (fukutin related protein) [NCBI Gene 79147]
- **Diseases:** limb-girdle muscular dystrophy (MONDO:0016971), dystrophinopathy (MONDO:0016147)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** PPA1 (inorganic pyrophosphatase 1) [NCBI Gene 5464] {aka HEL-S-66p, IOPPP, PP, PP1, SID6-8061}, PIK3C2A (phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha) [NCBI Gene 5286] {aka CPK, OCSKD, PI3-K-C2(ALPHA), PI3-K-C2A, PI3K-C2-alpha, PI3K-C2alpha}, COL6A1 (collagen type VI alpha 1 chain) [NCBI Gene 1291] {aka BTHLM1, BTHLM1A, OPLL, UCHMD1, UCHMD1A}, SGCD (sarcoglycan delta) [NCBI Gene 6444] {aka 35DAG, CMD1L, DAGD, LGMDR6, SG-delta, SGCDP}, COL6A2 (collagen type VI alpha 2 chain) [NCBI Gene 1292] {aka BTHLM1, BTHLM1B, PP3610, UCMD1, UCMD1B}, CMPK1 (cytidine/uridine monophosphate kinase 1) [NCBI Gene 51727] {aka CK, CMK, CMPK, UMK, UMP-CMPK, UMPK}, DYSF (dysferlin) [NCBI Gene 8291] {aka FER1L1, LGMD2B, LGMDR2, MMD1}, SGCG (sarcoglycan gamma) [NCBI Gene 6445] {aka 35DAG, A4, DAGA4, DMDA, DMDA1, LGMD2C}, GAA (alpha glucosidase) [NCBI Gene 2548] {aka IOPD, LOPD, LYAG}, FKRP (fukutin related protein) [NCBI Gene 79147] {aka FKTR, LGMD2I, LGMDR9, MDC1C, MDDGA5, MDDGB5}, POMK (protein O-mannose kinase) [NCBI Gene 84197] {aka MDDGA12, MDDGC12, SGK196}, CAPN3 (calpain 3) [NCBI Gene 825] {aka CANP3, CANPL3, LGMD2, LGMD2A, LGMDD4, LGMDR1}, FHL1 (four and a half LIM domains 1) [NCBI Gene 2273] {aka FCMSU, FHL-1, FHL1A, FHL1B, FLH1A, KYOT}, DMD (dystrophin) [NCBI Gene 1756] {aka BMD, CMD3B, DXS142, DXS164, DXS206, DXS230}, SGCB (sarcoglycan beta) [NCBI Gene 6443] {aka A3b, LGMD2E, LGMDR4, SGC}, LMNA (lamin A/C) [NCBI Gene 4000] {aka CDCD1, CDDC, CMD1A, CMT2B1, EMD2, FPL}, SGCA (sarcoglycan alpha) [NCBI Gene 6442] {aka 50DAG, ADL, DAG2, DMDA2, LGMD2D, LGMDR3}
- **Diseases:** intellectual disability (MESH:D008607), death (MESH:D003643), hyperCKemia (OMIM:123320), dorsal scoliosis (MESH:D012600), hypotonia (MESH:D009123), Alpha-sarcoglycanopathy (MESH:D058088), MPCR (MESH:D020422), CMD (MESH:C565145), calf hypertrophy (MESH:D006984), sex chromosome anomalies (MESH:D012729), muscle pain (MESH:D063806), cardiac dysfunction (MESH:D006331), hypertrophic cardiomyopathy (MESH:D002312), metabolic myopathies (MESH:D009135), gait difficulties (MESH:D020234), cognitive impairment (MESH:D003072), merosin-deficient congenital muscular dystrophy type 1C (MESH:C537384), neuromuscular disorders (MESH:D009468), EDMD (MESH:D020389), MD (MESH:D009136), Turner syndrome (MESH:D014424), Muscle-Eye-Brain disease (MESH:D058494), Pompe disease (MESH:D006009), Respiratory muscle involvement (MESH:C566343), atrophy (MESH:D001284), X-linked recessive (MESH:D040181), muscle weakness (MESH:D018908), dystrophic changes (MESH:D009402), AD (MESH:D000544), MDC1C (OMIM:606612), cardiomyopathy (MESH:D009202), LGMD (MESH:D049288), respiratory failure (MESH:D012131), Calpainopathy (MESH:C535895), gait disturbances (MESH:D020233), contracture (MESH:D003286), loss of ambulation (MESH:D051346), respiratory distress (MESH:D012128), cerebellar abnormalities (MESH:D002526), BMD (MESH:D020388), autosomal recessive disorder (MESH:D030342)
- **Chemicals:** Sephadex (MESH:C025614), calcium (MESH:D002118)
- **Species:** Homo sapiens (human, species) [taxon 9606], Bos taurus (bovine, species) [taxon 9913]
- **Mutations:** c.2129G>A, c.2258dup, 161delT, c.1016G>C, c.550del, c.716 T>G, c.2221del, c.868G>A, c.1012G>T, c.5419C>T, c.956+1G>A, 701delA, c.770T>G, c.2120A>G, c.1549_1550del, c.525delT, c.98G>C, rs781723572, rs374665929, c.271G>A, rs2509123275, rs2509113878, rs1318972801, c.838G>C, c.721G>A, c.823C>T, c.411dup, c.2173C>T, c.958A>G, c.371T>C, c.10171C>T, c.1714C>T, rs1173430388, 105946G>T, c.98-1G>C, c.637A>G, rs768090444, c.1364C>A, c.695_696insG, c.1A>G, c.399+1G>T, c.229C>T, c.3278T>C, c.161C>A, rs2509125625
- **Cell lines:** NM_000231.3 — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_TK84)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12936390/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12936390/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12936390/full.md

---
Source: https://tomesphere.com/paper/PMC12936390